Prithvi Mruthyunjaya, MD, MHS
Contact information
LOCATION
WEBSITE
https://profiles.stanford.edu/prithvi-mruthyunjaya
SPECIALTY
Ophthalmic Oncologist
Education and Fellowships
-OTHER
BS - Rensselaer Polytechnic Institute
-MEDICAL SCHOOL
Albany Medical College of Union College
-OTHER
Internship - University of Rochester/Strong Memorial Hospital
-RESIDENCY
Duke University
-FELLOWSHIP
Clinical and Research Fellowships in Vitreoretinal Surgery - Duke University Eye Center
-FELLOWSHIP
Clinical and Research Fellowship in Ocular Oncology - Moorfields Eye Hospital
Current Positions
Associate Professor of Ophthalmology,
Director, Ocular Oncology service
Byers Eye Institute at Stanford University
LOCATION
- Byers Eye Institute at Stanford
2452 Watson Court, Palo Alto, CA 94303
650-723-6995
Map and directions »
WEBSITE
https://profiles.stanford.edu/prithvi-mruthyunjaya
SPECIALTY
Ophthalmic Oncologist
Education and Fellowships
-OTHER
BS - Rensselaer Polytechnic Institute
-MEDICAL SCHOOL
Albany Medical College of Union College
-OTHER
Internship - University of Rochester/Strong Memorial Hospital
-RESIDENCY
Duke University
-FELLOWSHIP
Clinical and Research Fellowships in Vitreoretinal Surgery - Duke University Eye Center
-FELLOWSHIP
Clinical and Research Fellowship in Ocular Oncology - Moorfields Eye Hospital
Current Positions
Associate Professor of Ophthalmology,
Director, Ocular Oncology service
Byers Eye Institute at Stanford University
Biography
Prithvi Mruthyunjaya MD, MHS is Associate Professor of Ophthalmology at Stanford Univeristy, member of the Vitreoretinal Surgery Service and is the new Director of Ocular Oncology at the Byers Eye Institute. At the Duke Eye Center in Durham, NC, he finished his Ophthalmology residency, Chief Residency, and clinical-research fellowships in Vitreoretinal surgery followed by an Ocular Oncology fellowship at the Moorfields Eye Hosptial in London, UK. He has been recognized by the Heed, AOS-Knapp and Ronald G Michels foundations. He was on faculty at Duke from 2005-16 where developed an integrated Retina-Ocular Oncology program and was named a tenured Associate Professor of Ophthalmology and Radiation Oncology, Medical Director and Director of Ocular Oncology.
Dr. Mruthyunjaya’s clinical interest lies in the multi-disciplinary, vitreoretinal approach to ocular tumors and simulating conditions, and complex vitreoretinal disorders.. He manages both adult and pediatric ocular cancers with a focus on novel therapeutics, intraocular biopsy, and vision-saving strategies to reduce treatment toxicity. His academic contributions were recognized by the American Society of Retina Specialists with a Senior Honor Award. His passion lies in developing collaborative research networks and training the next generation of vitreoretinal surgeons.
Prithvi Mruthyunjaya MD, MHS is Associate Professor of Ophthalmology at Stanford Univeristy, member of the Vitreoretinal Surgery Service and is the new Director of Ocular Oncology at the Byers Eye Institute. At the Duke Eye Center in Durham, NC, he finished his Ophthalmology residency, Chief Residency, and clinical-research fellowships in Vitreoretinal surgery followed by an Ocular Oncology fellowship at the Moorfields Eye Hosptial in London, UK. He has been recognized by the Heed, AOS-Knapp and Ronald G Michels foundations. He was on faculty at Duke from 2005-16 where developed an integrated Retina-Ocular Oncology program and was named a tenured Associate Professor of Ophthalmology and Radiation Oncology, Medical Director and Director of Ocular Oncology.
Dr. Mruthyunjaya’s clinical interest lies in the multi-disciplinary, vitreoretinal approach to ocular tumors and simulating conditions, and complex vitreoretinal disorders.. He manages both adult and pediatric ocular cancers with a focus on novel therapeutics, intraocular biopsy, and vision-saving strategies to reduce treatment toxicity. His academic contributions were recognized by the American Society of Retina Specialists with a Senior Honor Award. His passion lies in developing collaborative research networks and training the next generation of vitreoretinal surgeons.
